Hematology Transfusion and Cell Therapy · Oct 2026

Characterization of clonal hematopoiesis of indeterminate potential as a genetic risk factor in patients diagnosed with BCR::ABL1-negative myeloproliferative neoplasms

By SOARES GRFN, GARCIA CAB, Medeiros M et al.

BCR::ABL1-negative myeloproliferative neoplasms (NMPs) are chronic clonal diseases characterized by the malignant transformation and expansion of mature cells of the myeloid lineage. Their pathogenesis arises from somatic mutations acquired in hematopoietic stem cells (CTHs), primarily involving classical driver mutations in the JAK2, CALR, and MPL genes. Certain mutational variants, particularly JAK2V617F, may also arise in clonal hematopoiesis of indeterminate potential (CHIP, from the English Clonal Hematopoiesis of Indeterminate Potential), a condition associated with aging and characterized by the expansion of CTHs carrying somatic mutations in the absence of malignancy criteria for a hematologic neoplasm. While CHIP most frequently involves variants in genes such as DNMT3A, TET2, and ASXL1 (“DTA mutations''), the overlap in the mutational spectrum between CHIP and NMPs has suggested a continuum between age-associated clonal hematopoiesis and myeloid transformation. Both conditions, CHIP and NMPs, have independently shown an increased risk of adverse cardiovascular events and increased thrombotic risk; however, it remains poorly understood whether CHIP-type mutational variants would modify thrombotic risk in patients with a previously established diagnosis of NMP. Therefore, the objective of this research was to investigate whether the mutational profile associated with CHIP contributes to increased thrombotic outcomes and to risk stratification. We analyzed data from 46 individuals (n = 46) from a cohort of 231 patients diagnosed with NMP (polycythemia vera, essential thrombocythemia, or primary myelofibrosis), followed as outpatients by Hematology in our service at Hospital das Clínicas of the Ribeirão Preto Medical School of the University of São Paulo (HCFMRP-USP), using next-generation sequencing (NGS) of a panel of 55 genes associated with myeloid conditions, including NMPs and CHIP. The cohort was initially divided into two groups: 26 patients without prior thrombosis (TN group) and 19 with previous thrombotic events (TP group). General clinical data, such as age, sex, presence of a classical driver mutation (JAK2, CALR, MPL), and cardiovascular risk factors, were comparable between the groups, suggesting that the occurrence of thrombosis could not be attributed solely to the differences observed in these clinical variables. A total of 23 thrombotic events distributed throughout the cohort were retrospectively identified, most of which were arterial, particularly the cerebrovascular outcome (stroke/transient ischemic attack). To characterize the mutational profile related to CHIP and thrombotic risk within the study, in correlation with the clinical data, NGS data were analyzed, including Tier 1 or Tier 2 pathogenic variants, with a focus on the following genes: JAK2, CALR, MPL, TET2, ASXL1, and DNMT3A. We performed a multivariate analysis of all the information then gathered within n = 46, with subsequent biostatistical processing, to better understand the presence or absence of thrombotic outcomes in the context of NMPs, which have high morbidity and mortality.

doi.org/10.1016/j.htct.2026.107488Open accessPopulations

AgingResearch.News